1. Home
  2. MDGL

MDGL

Madrigal Pharmaceuticals Inc.

Logo Madrigal Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Founded: 2011 Country:
United States
United States
Employees: N/A City: WEST CONSHOHOCKEN
Market Cap: 5.2B IPO Year: N/A
Target Price: $375.90 AVG Volume (30 days): 571.5K
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -19.99 EPS Growth: N/A
52 Week Low/High: $119.76 - $322.67 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 326.34%

Share on Social Networks: